Runx2 transcriptome of prostate cancer cells: Insights into invasiveness and bone metastasis

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Baniwal, Sanjeev K ^a   Khalid, Omar ^a   Gabet, Yankel ^a   Shah, Ruchir R ^c,d   Purcell, Daniel J ^a   Mav, Deepak ^c   Kohn Gabet, Alice E ^a   Shi, Yunfan ^a   Coetzee, Gerhard A ^a,b   Frenkel, Baruch ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SRA International   (United States)

^d National Institute of Environmental Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; SMAD3 PROTEIN; SPHINGOSINE KINASE 1; STROMAL CELL DERIVED FACTOR 1; SYNDECAN 2; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTOME; ACTIN BINDING PROTEIN; CST7 PROTEIN, HUMAN; CYSTATIN; DUSP1 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; RUNX2 PROTEIN, HUMAN; SDC2 PROTEIN, HUMAN; SH3PXD2A PROTEIN, HUMAN; TUMOR MARKER; TWF1 PROTEIN, HUMAN; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL HOMING; COMPUTER MODEL; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; PHENOTYPE; PROSTATE CANCER; TRANSCRIPTOMICS; UPREGULATION; APOPTOSIS; BONE TUMOR; CELL CYCLE; CELL PROLIFERATION; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; METASTASIS; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CYSTATINS; DUAL SPECIFICITY PHOSPHATASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICROFILAMENT PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNDECAN-2; TUMOR MARKERS, BIOLOGICAL;

EID: 77956880700     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-258     Document Type: Article

References (124)

1. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754. 10.1016/S0092-8674(00)80257-3, 9182762.
2. Cameron ER, Neil JC. The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene 2004, 23:4308-4314. 10.1038/sj.onc.1207130, 15156187.
3. Lo Coco F, Pisegna S, Diverio D. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica 1997, 82:364-370.
4. Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, Brenner O, Berke G, et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA 2003, 100:7731-7736. 10.1073/pnas.1232420100, 164656, 12796513.
5. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764. 10.1016/S0092-8674(00)80258-5, 9182763.
6. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771. 10.1016/S0092-8674(00)80259-7, 9182764.
7. Levanon D, Bettoun D, Harris-Cerruti C, Woolf E, Negreanu V, Eilam R, Bernstein Y, Goldenberg D, Xiao C, Fliegauf M, et al. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. Embo J 2002, 21:3454-3463. 10.1093/emboj/cdf370, 125397, 12093746.
8. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 2004, 23:4198-4208. 10.1038/sj.onc.1207755, 15156173.
9. Bae SC, Choi JK. Tumor suppressor activity of RUNX3. Oncogene 2004, 23:4336-4340. 10.1038/sj.onc.1207286, 15156190.
10. Levanon D, Groner Y. Structure and regulated expression of mammalian RUNX genes. Oncogene 2004, 23:4211-4219. 10.1038/sj.onc.1207670, 15156175.
11. Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Ito Y, Chayama K, Yasui W. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 2004, 71:137-143. 10.1159/000076468, 15051926.
12. Rossetti S, Van Unen L, Touw IP, Hoogeveen AT, Sacchi N. Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation. Oncogene 2005, 24:5325-5332. 10.1038/sj.onc.1208651, 16007222.
13. Kilbey A, Blyth K, Wotton S, Terry A, Jenkins A, Bell M, Hanlon L, Cameron ER, Neil JC. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res 2007, 67:11263-11271. 10.1158/0008-5472.CAN-07-3016, 2562449, 18056452.
14. Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA, Stein JL, Lian JB, van Wijnen AJ, Stein GS. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 2007, 104:19861-19866. 10.1073/pnas.0709650104, 2148388, 18077419.
15. Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem 2005, 280:20274-20285. 10.1074/jbc.M413665200, 2895256, 15781466.
16. Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 2003, 63:5357-5362.
17. Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR, Holloway AJ, et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004, 167:925-934. 10.1083/jcb.200409187, 2172443, 15583032.
18. Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron ER, Neil JC, Stewart M. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 2001, 20:295-302. 10.1038/sj.onc.1204090, 11313958.
19. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005, 5:376-387. 10.1038/nrc1607, 15864279.
20. Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 2006, 99:1233-1239. 10.1002/jcb.20958, 16795049.
21. Otto F, Kanegane H, Mundlos S. Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat 2002, 19:209-216. 10.1002/humu.10043, 11857736.
22. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2009, 811-821. 2820596, 19915614.
23. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999, 39:246-261. 10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U, 10344214.
24. Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, Ling MT, Wong YC. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 2009, 15:4322-4335. 10.1158/1078-0432.CCR-08-3157, 19509141.
25. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001, 47:212-221. 10.1002/pros.1065, 11351351.
26. Selvamurugan N, Kwok S, Partridge NC. Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem 2004, 279:27764-27773. 10.1074/jbc.M312870200, 15084595.
27. Lim M, Zhong C, Yang S, Bell AM, Cohen MB, Roy-Burman P. Runx2 regulates survivin expression in prostate cancer cells. Lab Invest 90:222-233. 10.1038/labinvest.2009.128, 2815261, 19949374.
28. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005, 25:8581-8591. 10.1128/MCB.25.19.8581-8591.2005, 1265732, 16166639.
29. Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, Bellahcene A, Van Wijnen AJ, Young MF, Lian JB, et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003, 63:2631-2637.
30. Zelzer E, Glotzer DJ, Hartmann C, Thomas D, Fukai N, Soker S, Olsen BR. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 2001, 106:97-106. 10.1016/S0925-4773(01)00428-2, 11472838.
31. Geoffroy V, Kneissel M, Fournier B, Boyde A, Matthias P. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 2002, 22:6222-6233. 10.1128/MCB.22.17.6222-6233.2002, 134019, 12167715.
32. Maruyama Z, Yoshida CA, Furuichi T, Amizuka N, Ito M, Fukuyama R, Miyazaki T, Kitaura H, Nakamura K, Fujita T, et al. Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Dev Dyn 2007, 236:1876-1890. 10.1002/dvdy.21187, 17497678.
33. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C, Chung LW. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002, 277:2468-2476. 10.1074/jbc.M105947200, 11684680.
34. Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN, Nickerson JA, et al. Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res 2009, 69:6807-6814. 10.1158/0008-5472.CAN-09-1471, 2742766, 19690135.
35. Kayed H, Jiang X, Keleg S, Jesnowski R, Giese T, Berger MR, Esposito I, Lohr M, Friess H, Kleeff J. Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer 2007, 97:1106-1115. 10.1038/sj.bjc.6603984, 2360444, 17876328.
36. Endo T, Ohta K, Kobayashi T. Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells. J Clin Endocrinol Metab 2008, 93:2409-2412. 10.1210/jc.2007-2805, 18381576.
37. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983, 43:1809-1818.
38. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994, 57:406-412. 10.1002/ijc.2910570319, 8169003.
39. Shin KJ, Wall EA, Zavzavadjian JR, Santat LA, Liu J, Hwang JI, Rebres R, Roach T, Seaman W, Simon MI, Fraser ID. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci USA 2006, 103:13759-13764. 10.1073/pnas.0606179103, 1557799, 16945906.
40. Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T, Yamamoto M, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell 2001, 104:755-767. 10.1016/S0092-8674(01)00271-9, 11257229.
41. Sudhakar S, Li Y, Katz MS, Elango N. Translational regulation is a control point in RUNX2/Cbfa1 gene expression. Biochem Biophys Res Commun 2001, 289:616-622. 10.1006/bbrc.2001.6033, 11716520.
42. Ducy P, Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 1995, 15:1858-1869. 230411, 7891679.
43. Vaes BL, Ducy P, Sijbers AM, Hendriks JM, van Someren EP, de Jong NG, van den Heuvel ER, Olijve W, van Zoelen EJ, Dechering KJ. Microarray analysis on Runx2-deficient mouse embryos reveals novel Runx2 functions and target genes during intramembranous and endochondral bone formation. Bone 2006, 39:724-738. 10.1016/j.bone.2006.04.024, 16774856.
44. Cheung M, Chaboissier MC, Mynett A, Hirst E, Schedl A, Briscoe J. The transcriptional control of trunk neural crest induction, survival, and delamination. Dev Cell 2005, 8:179-192. 10.1016/j.devcel.2004.12.010, 15691760.
45. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 2009, 106:3913-3918. 10.1073/pnas.0810617106, 2656179, 19237579.
46. Caputo E, Manco G, Mandrich L, Guardiola J. A novel aspartyl proteinase from apocrine epithelia and breast tumors. J Biol Chem 2000, 275:7935-7941. 10.1074/jbc.275.11.7935, 10713110.
47. Chiang L, Contreras L, Chiang J, Ward PH. Human prostatic gastricsinogen: the precursor of seminal fluid acid proteinase. Arch Biochem Biophys 1981, 210:14-20. 10.1016/0003-9861(81)90158-2, 6794457.
48. Morita M, Yoshiuchi N, Arakawa H, Nishimura S. CMAP: a novel cystatin-like gene involved in liver metastasis. Cancer Res 1999, 59:151-158.
49. Sherbet GV. Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Lett 2009, 280:15-30. 10.1016/j.canlet.2008.10.037, 19059703.
50. Matsuura I, Lai CY, Chiang KN. Functional interaction between Smad3 and S100A4 (metastatin-1) for TGF-beta-mediated cancer cell invasiveness. Biochem J 2010, 426:327-335. 10.1042/BJ20090990, 20070253.
51. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 2006, 66:3034-3043. 10.1158/0008-5472.CAN-05-2177, 16540652.
52. Larsen M, Artym VV, Green JA, Yamada KM. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 2006, 18:463-471. 10.1016/j.ceb.2006.08.009, 16919434.
53. Schmidt KL, Marcus-Gueret N, Adeleye A, Webber J, Baillie D, Stringham EG. The cell migration molecule UNC-53/NAV2 is linked to the ARP2/3 complex by ABI-1. Development 2009, 136:563-574. 10.1242/dev.016816, 19168673.
54. Sekerkova G, Loomis PA, Changyaleket B, Zheng L, Eytan R, Chen B, Mugnaini E, Bartles JR. Novel espin actin-bundling proteins are localized to Purkinje cell dendritic spines and bind the Src homology 3 adapter protein insulin receptor substrate p53. J Neurosci 2003, 23:1310-1319. 2854510, 12598619.
55. Riederer BM. Microtubule-associated protein 1B, a growth-associated and phosphorylated scaffold protein. Brain Res Bull 2007, 71:541-558. 10.1016/j.brainresbull.2006.11.012, 17292797.
56. Maul RS, Song Y, Amann KJ, Gerbin SC, Pollard TD, Chang DD. EPLIN regulates actin dynamics by cross-linking and stabilizing filaments. J Cell Biol 2003, 160:399-407. 10.1083/jcb.200212057, 2172667, 12566430.
57. Paavilainen VO, Bertling E, Falck S, Lappalainen P. Regulation of cytoskeletal dynamics by actin-monomer-binding proteins. Trends Cell Biol 2004, 14:386-394. 10.1016/j.tcb.2004.05.002, 15246432.
58. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113:6085-6093. 10.1182/blood-2008-12-196618, 19380869.
59. Mazzinghi B, Ronconi E, Lazzeri E, Sagrinati C, Ballerini L, Angelotti ML, Parente E, Mancina R, Netti GS, Becherucci F, et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med 2008, 205:479-490. 10.1084/jem.20071903, 2271008, 18268039.
60. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007, 292:C987-995. 10.1152/ajpcell.00406.2006, 16943240.
61. Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004, 84:1666-1676. 10.1038/labinvest.3700181, 15467730.
62. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005, 65:465-472.
63. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002, 62:1832-1837.
64. Ara T, Tokoyoda K, Sugiyama T, Egawa T, Kawabata K, Nagasawa T. Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 2003, 19:257-267. 10.1016/S1074-7613(03)00201-2, 12932359.
65. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848. 10.1126/science.283.5403.845, 9933168.
66. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J, Castronovo V. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998, 90:1000-1008. 10.1093/jnci/90.13.1000, 9665149.
67. Waltregny D, Bellahcene A, de Leval X, Florkin B, Weidle U, Castronovo V. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 2000, 15:834-843. 10.1359/jbmr.2000.15.5.834, 10804012.
68. Zhang JH, Tang J, Wang J, Ma W, Zheng W, Yoneda T, Chen J. Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol 2003, 23:1043-1048.
69. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, Loening SA, Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004, 111:783-791. 10.1002/ijc.20314, 15252851.
70. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001, 20:333-349. 10.1023/A:1015599831232, 12085970.
71. Liu H, Holm M, Xie XQ, Wolf-Watz M, Grundstrom T. AML1/Runx1 recruits calcineurin to regulate granulocyte macrophage colony-stimulating factor by Ets1 activation. J Biol Chem 2004, 279:29398-29408. 10.1074/jbc.M403173200, 15123671.
72. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007, 13:62-69. 10.1038/nm1519, 17159986.
73. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899. 10.1016/j.cell.2010.01.025, 20303878.
74. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004, 4:11-22. 10.1038/nrc1252, 14708024.
75. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296. 10.1016/j.cell.2004.07.013, 15294155.
76. Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M, Saeki Y, Vacher J, Proia RL, Germain RN. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009, 458:524-528. 10.1038/nature07713, 2785034, 19204730.
77. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 2008, 9:662-673. 10.2174/138945008785132402, 2674575, 18691013.
78. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006, 9:225-238. 10.1016/j.ccr.2006.02.023, 16530706.
79. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B, Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 2005, 65:11667-11675. 10.1158/0008-5472.CAN-05-2702, 16357178.
80. Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J, Zielenska M. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 10:202. 10.1186/1471-2407-10-202, 2875220, 20465837.
81. Vanhara P, Lincova E, Kozubik A, Jurdic P, Soucek K, Smarda J. Growth/differentiation factor-15 inhibits differentiation into osteoclasts--a novel factor involved in control of osteoclast differentiation. Differentiation 2009, 78:213-222. 10.1016/j.diff.2009.07.008, 19695766.
82. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006, 25:589-600. 10.1007/s10555-006-9032-0, 17165130.
83. Teplyuk NM, Haupt LM, Ling L, Dombrowski C, Mun FK, Nathan SS, Lian JB, Stein JL, Stein GS, Cool SM, van Wijnen AJ. The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts. J Cell Biochem 2009, 107:144-154. 10.1002/jcb.22108, 2918404, 19259985.
84. Essner JJ, Chen E, Ekker SC. Syndecan-2. Int J Biochem Cell Biol 2006, 38:152-156. 10.1016/j.biocel.2005.08.012, 16198615.
85. Park H, Kim Y, Lim Y, Han I, Oh ES. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 2002, 277:29730-29736. 10.1074/jbc.M202435200, 12055189.
86. Granes F, Urena JM, Rocamora N, Vilaro S. Ezrin links syndecan-2 to the cytoskeleton. J Cell Sci 2000, 113(Pt 7):1267-1276.
87. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1:944-949. 10.1038/nm0995-944, 7585222.
88. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004, 64:994-999. 10.1158/0008-5472.CAN-03-1382, 14871830.
89. Street J, Bao M, deGuzman L, Bunting S, Peale FV, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 2002, 99:9656-9661. 10.1073/pnas.152324099, 124965, 12118119.
90. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001, 22:201-207. 10.1016/S0165-6147(00)01676-X, 11282421.
91. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676. 10.1038/nm0603-669, 12778165.
92. Vaidyanathan G, Cismowski MJ, Wang G, Vincent TS, Brown KD, Lanier SM. The Ras-related protein AGS1/RASD1 suppresses cell growth. Oncogene 2004, 23:5858-5863. 10.1038/sj.onc.1207774, 15184869.
93. Horsch K, de Wet H, Schuurmans MM, Allie-Reid F, Cato AC, Cunningham J, Burrin JM, Hough FS, Hulley PA. Mitogen-activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol Endocrinol 2007, 21:2929-2940. 10.1210/me.2007-0153, 2838148, 17761948.
94. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999, 35:403-409. 10.1007/s11626-999-0115-4, 10462204.
95. Hecht J, Seitz V, Urban M, Wagner F, Robinson PN, Stiege A, Dieterich C, Kornak U, Wilkening U, Brieske N, et al. Detection of novel skeletogenesis target genes by comprehensive analysis of a Runx2(-/-) mouse model. Gene Expr Patterns 2007, 7:102-112. 10.1016/j.modgep.2006.05.014, 16829211.
96. Young DW, Hassan MQ, Yang XQ, Galindo M, Javed A, Zaidi SK, Furcinitti P, Lapointe D, Montecino M, Lian JB, et al. Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proc Natl Acad Sci USA 2007, 104:3189-3194. 10.1073/pnas.0611419104, 1805558, 17360627.
97. Wotton S, Terry A, Kilbey A, Jenkins A, Herzyk P, Cameron E, Neil JC. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 2008, 27:5856-5866. 10.1038/onc.2008.195, 2562521, 18560354.
98. Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem 2005, 96:484-489. 10.1002/jcb.20557, 16052475.
99. Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, Coetzee GA, Frenkel B. Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology 2008, 149:5984-5995. 10.1210/en.2008-0680, 2613062, 18755791.
100. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005, 102:1454-1459. 10.1073/pnas.0409121102, 547873, 15665096.
101. Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 2009, 23:1203-1214. 10.1210/me.2008-0470, 2718746, 19389811.
102. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 2007, 101:873-886. 10.1002/jcb.21214, 17387734.
103. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664. 10.1056/NEJMra030831, 15084698.
104. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593. 10.1038/nrc867, 12154351.
105. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005, 5:21-28. 10.1038/nrc1528, 15630412.
106. Phillips JE, Garcia AJ. Retroviral-mediated gene therapy for the differentiation of primary cells into a mineralizing osteoblastic phenotype. Methods Mol Biol 2008, 433:333-354. full_text, 18679633.
107. Kim JH, Yang CK, Heo K, Roeder RG, An W, Stallcup MR. CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes. Mol Cell 2008, 31:510-519. 10.1016/j.molcel.2008.08.001, 2562329, 18722177.
108. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B 1995, 57:289-300.
109. Toth M, Fridman R. Assessment of Gelatinases (MMP-2 and MMP-9 by Gelatin Zymography. Metastasis Research Protocols 2008, 57:163-174.
110. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 10.1038/nrc822, 12189386.
111. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006, 16:253-264. 10.1016/j.semcancer.2006.07.014, 16904903.
112. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall'Olio V, Zardo G, Nervi C, Bernard L, Amati B. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 2006, 8:764-770. 10.1038/ncb1434, 16767079.
113. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213. 10.1084/jem.20052144, 2118398, 16940167.
114. Bellou S, Hink MA, Bagli E, Panopoulou E, Bastiaens PI, Murphy C, Fotsis T. VEGF autoregulates its proliferative and migratory ERK1/2 and p38 cascades by enhancing the expression of DUSP1 and DUSP5 phosphatases in endothelial cells. Am J Physiol Cell Physiol 2009, 297:C1477-1489. 10.1152/ajpcell.00058.2009, 19741200.
115. Liu F, Verin AD, Wang P, Day R, Wersto RP, Chrest FJ, English DK, Garcia JG. Differential regulation of sphingosine-1-phosphate- and VEGF-induced endothelial cell chemotaxis. Involvement of G(ialpha2)-linked Rho kinase activity. Am J Respir Cell Mol Biol 2001, 24:711-719.
116. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000, 106:951-961. 10.1172/JCI10905, 314347, 11032855.
117. Donaudy F, Zheng L, Ficarella R, Ballana E, Carella M, Melchionda S, Estivill X, Bartles JR, Gasparini P. Espin gene (ESPN) mutations associated with autosomal dominant hearing loss cause defects in microvillar elongation or organisation. J Med Genet 2006, 43:157-161. 10.1136/jmg.2005.032086, 2564636, 15930085.
118. Bartles JR, Wierda A, Zheng L. Identification and characterization of espin, an actin-binding protein localized to the F-actin-rich junctional plaques of Sertoli cell ectoplasmic specializations. J Cell Sci 1996, 109(Pt 6):1229-1239.
119. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsch B, Richards LJ, Kolodkin AL, Ginty DD. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell 2003, 5:45-57. 10.1016/S1534-5807(03)00169-2, 12852851.
120. Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 2007, 6:481-486. 10.4161/cbt.6.4.4201, 18027437.
121. Tanner SL, Franzen R, Jaffe H, Quarles RH. Evidence for expression of some microtubule-associated protein 1B in neurons as a plasma membrane glycoprotein. J Neurochem 2000, 75:553-562. 10.1046/j.1471-4159.2000.0750553.x, 10899930.
122. Stylli SS, Stacey TT, Verhagen AM, Xu SS, Pass I, Courtneidge SA, Lock P. Nck adaptor proteins link Tks5 to invadopodia actin regulation and ECM degradation. J Cell Sci 2009, 122:2727-2740. 10.1242/jcs.046680, 2909319, 19596797.
123. Donalies M, Cramer M, Ringwald M, Starzinski-Powitz A. Expression of M-cadherin, a member of the cadherin multigene family, correlates with differentiation of skeletal muscle cells. Proc Natl Acad Sci USA 1991, 88:8024-8028. 10.1073/pnas.88.18.8024, 52438, 1840697.
124. Hu SI, Carozza M, Klein M, Nantermet P, Luk D, Crowl RM. Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 1998, 273:34406-34412. 10.1074/jbc.273.51.34406, 9852107.